| 纯度 | > 90 % Densitometry. |
| 种属 | Human |
| 靶点 | BMPR1A |
| Uniprot No | P36894 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 177-532aa |
| 氨基酸序列 | KHYCKSISSRRRYNRDLEQDEAFIPVGESLKDLIDQSQSSGSGSGLPLLVQRTIAKQIQMVRQVGKGRYGEVWMGKWRGEKVAVKVFFTTEEASWFRETEIYQTVLMRHENILGFIAADIKGTGSWTQLYLITDYHENGSLYDFLKCATLDTRALLKLAYSAACGLCHLHTEIYGTQGKPAIAHRDLKSKNILIKKNGSCCIADLGLAVKFNSDTNEVDVPLNTRVGTKRYMAPEVLDESLNKNHFQPYIMADIYSFGLIIWEMARRCITGGIVEEYQLPYYNMVPSDPSYEDMREVVCVKRLRPIVSNRWNSDECLRAVLKLMSECWAHNPASRLTALRIKKTLAKMVESQDVKI |
| 预测分子量 | 56.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BMPR1A重组蛋白的3篇参考文献示例(注：文献为虚构示例，仅供格式参考)：
---
1. **文献名称**：*Expression and Functional Characterization of Recombinant BMPR1A in Mammalian Cells*
**作者**：Zhang L, et al.
**摘要**：本研究通过哺乳动物表达系统成功制备了重组人BMPR1A胞外结构域蛋白，验证了其与BMP2配体的高亲和力结合能力，并证明其可通过激活Smad信号通路调控成骨细胞分化。
---
2. **文献名称**：*Structural Insights into BMPR1A Activation by Cryo-EM*
**作者**：Chen W, et al.
**摘要**：利用冷冻电镜技术解析了重组BMPR1A与BMP9配体复合物的三维结构，揭示了受体激酶活性调控的关键构象变化，为靶向BMP信号通路的药物设计提供了结构基础。
---
3. **文献名称**：*BMPR1A Recombinant Protein Enhances Bone Regeneration in a Mouse Model*
**作者**：Kim S, et al.
**摘要**：在大肠杆菌中表达并纯化功能性BMPR1A重组蛋白，通过动物实验证明其能显著促进小鼠颅骨缺损模型的骨再生，机制涉及上调Runx2和Osteocalcin表达。
---
(若需补充真实文献，建议在PubMed或Web of Science中检索关键词：`"BMPR1A" AND "recombinant protein"`，并筛选近年高被引研究。)
**Background of BMPR1A Recombinant Protein**
BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β (transforming growth factor-beta) superfamily. It plays a critical role in mediating cellular responses to bone morphogenetic proteins (BMPs), which are essential regulators of embryonic development, cell differentiation, apoptosis, and tissue homeostasis. BMPR1A binds BMP ligands (e.g., BMP-2. BMP-4) to form a heteromeric complex with type II receptors, initiating downstream signaling via SMAD (SMAD1/5/8) and non-SMAD pathways (e.g., MAPK, PI3K/AKT).
The recombinant BMPR1A protein is engineered *in vitro* to mimic the native receptor's functional domains, often excluding transmembrane regions for solubility. Produced in systems like mammalian cells or *E. coli*, it retains ligand-binding capability and kinase activity. Researchers use it to study BMP signaling mechanisms, screen for agonists/antagonists, or restore dysregulated pathways in disease models.
BMPR1A mutations are linked to disorders like juvenile polyposis syndrome (JPS) and hereditary colorectal cancer, underscoring its tumor-suppressive role. Recombinant BMPR1A aids in elucidating these pathologies and developing targeted therapies. Its structural analysis (e.g., ligand-binding interfaces, kinase domains) also informs drug design. Overall, BMPR1A recombinant protein serves as a vital tool for advancing research in developmental biology, oncology, and regenerative medicine.
×
